Press Release

Media Contact
Martin Kunze
T +49 6172 609-2115
martin.kunze@fresenius.com
Contact for analysts andinvestors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com

April 24, 2018

Fresenius Medical Care wins Red Dot design award for advanced
bloodline system used in hemodialysis
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has
won the Red Dot Award: Product Design for the company’s 6008 CAREset. This advanced
all-in-one disposable with pre-connected bloodlines combines with the 6008 dialysismachine to form the 6008 CAREsystem. The 6008 CAREset was developed for use in all
hemodialysis treatments, including Fresenius Medical Care’s advanced HighVolumeHDF
dialysis therapy.
The Red Dot Award for outstanding international product design has been presented
annually since 1955 by the Design Center North Rhine-Westphalia in Essen, Germany.
More than 6,300 products from companies in 59 countries were entered into this year’scompetition.
“The 6008 CAREsystem stands for reduced complexity, and minimizes the number ofhandling steps during dialysis,” said Dr. Olaf Schermeier, Fresenius Medical Care’s Chief
Executive Officer for Global Research and Development. “The innovative design of the6008 CAREset makes a key contribution to this. Because the bloodlines are preconnected, the medical staff has more time to provide direct patient care. We aredelighted about the recognition that this internationally renowned award will bring.”
Handling steps are reduced not only during dialysis, but during the set-up anddisconnection phases before and after each treatment. The 6008 CAREset is simply
inserted into the dialysis machine, eliminating the need to manually connect thePage 1/2bloodlines: This limits potential connection errors, which makes treatments safer. And inaddition to being more cost efficient, the reduced amount of waste generated during atreatment makes the 6008 CAREsystem environmentally friendly.
Dialysis machines, bloodline systems and dialyzers – the latter often dubbed “artificialkidneys” because this is where the blood is actually cleaned – are the most important
products for treating chronic kidney disease. During treatment, the dialysis machine
pumps the patient’s blood through bloodlines, monitors its circulation through thedialyzer, and adds anti-coagulants. Treatments are generally carried out three times
weekly, and take between three and six hours each.
About half of all dialysis machines and dialyzers sold worldwide are produced byFresenius Medical Care.
More information about the Red Dot Award is available at https://en.red-dot.org.
Note to the media: Images of the 6008 CAREsystem can be foundat https://tinyurl.com/ybvxz9bj.

Fresenius Medical Care is the world's largest provider of products and services for individuals withrenal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment.
Through its network of 3,752 dialysis clinics, Fresenius Medical Care provides dialysis treatmentsfor 320,960 patients around the globe. Fresenius Medical Care is also the leading provider of
dialysis products such as dialysis machines or dialyzers. Along with the core business, the company
focuses on expanding the range of related medical services in the field of Care Coordination.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock
Exchange (FMS).
For more information visit the Company’s website at www.freseniusmedicalcare.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual
results could differ materially from those described in these forward-looking statements due to certain factors,
including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate
fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These andother risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S.
Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this release.

Page 2/2